title: [Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal].
abstract: We report a case of drug eruption (erythema multiforme type) in a 54-year-old woman, following concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal. Chemotherapy comprised one cycle of mitomycin C 10 mg/m2/day (intravenous bolus injection)on day 1 and 5-fluorouracil(5-FU)1, 000 mg/m 2/day (continuous intravenous infusion) on days 1-4 of radiotherapy. External irradiation of the pelvic space was performed, using daily fractions of 1. 5 Gy(total dose, 33 Gy). From day 4 after chemoradiotherapy, erythema appeared proximal to the forearm site used for drug administration. On day 6, erythema was noted on the trunk, hip and thigh. We suspected erythema multiforme based on the appearance of wheals and target lesions of the skin and a patient history of chemoradiotherapy. Steroids were administered orally, which resolved systemic eruption at week 2. The patient also experienced grade 3 leukocytopenia, neutropenia, thrombopenia, diarrhea, and anorexia. Although we could not provide sufficient chemotherapy and radiation therapy due to severe side effects, squamous cell carcinoma of the anal canal responded extremely well with a marked decrease in complete response. We surmise that the drug eruption was associated with 5-FU. Concurrent chemoradiotherapy is safe and effective for squamous cell carcinoma of the anal canal, but care is required to prevent drug eruption during treatment.
authors.affiliation: Department of Radiology, Kurume University School of Medicine.
authors.forename: Shunji
authors.initials: S
authors.lastname: Arikawa
authors.forename: Masafumi
authors.initials: M
authors.lastname: Uchida
authors.forename: Etsuyo
authors.initials: E
authors.lastname: Ogoh
authors.forename: Jun
authors.initials: J
authors.lastname: Uozumi
authors.forename: Seigo
authors.initials: S
authors.lastname: Yoshida
authors.forename: Yuko
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Hayato
authors.initials: H
authors.lastname: Kaida
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ishibashi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirouzu
authors.forename: Naofumi
authors.initials: N
authors.lastname: Hayabuchi
mesh_terms: D001003:Anal Canal / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D003131:Combined Modality Therapy / Q000009:adverse effects; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013256:Steroids / Q000627:therapeutic use
chemical_list: D013256:Steroids; D016685:Mitomycin; D005472:Fluorouracil